Seeking Alpha HealthcareOriginal article
ADMA reiterates 2026 guidance of $530M-$560M revenue while targeting $200M+ in share repurchases
EarningsPositive
AI Analysis
Summary
ADMA Biologics reiterated its 2026 revenue guidance of $530M-$560M and announced plans for $200M+ in share repurchases.
Financial Highlights
Revenue
$530M-$560M
Guidance
2026 revenue guidance of $530M-$560M; $200M+ in share repurchases
Importance:4/10
Sentiment:
0.30
guidanceshare repurchaserevenue outlook
Related Companies
Read the original article
Published by Seeking Alpha Healthcare on August 5, 2026 11:33 PM